A Science and Retraction Watch investigation revisited the fatal outcome of an experimental gene-editing intervention in China, where a 6-year-old girl died after receiving a brain-directed base editor delivered via viral infusion. The report points to unusual arrangements and questions around ethics and oversight, while emphasizing that the trial outcome was not made public at the time. The account describes a treatment that the family paid for, based on preclinical work in animal models, with clinicians reportedly characterizing risks as modest. Investigators suggest an immune reaction to the viral delivery system may have contributed to the fatal course. The story matters for biotech developers because it underscores how governance and trial transparency—especially for gene-editing platforms—can become decisive risk factors once clinical studies move beyond well-established protocols.